<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006669</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068283</org_study_id>
    <secondary_id>WHC-99365</secondary_id>
    <secondary_id>NCI-V00-1630</secondary_id>
    <nct_id>NCT00006669</nct_id>
  </id_info>
  <brief_title>Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill&#xD;
      them or deliver cancer-killing substances to them without harming normal cells. Drugs used in&#xD;
      chemotherapy use different ways to kill cancer cells. Combining monoclonal antibody therapy&#xD;
      with chemotherapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of rituximab followed by combination&#xD;
      chemotherapy in treating patients who have refractory or recurrent non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate in patients with refractory or recurrent CD20+&#xD;
      intermediate grade B-cell non-Hodgkin's lymphoma treated with rituximab followed by&#xD;
      etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH). II. Determine&#xD;
      the toxicity of the regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients receive rituximab IV over 4-10 hours on day 1&#xD;
      followed by etoposide, vincristine, and doxorubicin IV continuously on days 4-7,&#xD;
      cyclophosphamide IV over 5-30 minutes on day 8 and oral prednisone on days 4-8. Patients also&#xD;
      receive sargramostim (GM-CSF) subcutaneously beginning on day 9 until blood counts recover.&#xD;
      Treatment repeats every 21 days for a maximum of 8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 1999</start_date>
  <completion_date>January 2000</completion_date>
  <primary_completion_date>January 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPOCH regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of intermediate grade B-cell CD20+ non-Hodgkin's&#xD;
        lymphoma Failed to achieve initial complete response (CR) after at least 2 courses of&#xD;
        standard chemotherapy OR Relapsed after CR and not eligible for autologous bone marrow&#xD;
        transplant Measurable disease defined as one of the following: Bidimensionally measurable&#xD;
        disease at least 2 cm in diameter by radiograph or CT scan Enlarged spleen extending at&#xD;
        least 2 cm below the costal due to lymphomatous involvement Enlarged liver with focal&#xD;
        lesions on CT scan or biopsy proven lesions Lymphomatous hepatic involvement must be biopsy&#xD;
        proven for the liver to be sole area of measurable disease No evidence of CNS involvement A&#xD;
        new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The&#xD;
        terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of&#xD;
        &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
        terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not&#xD;
        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3* Platelet count at&#xD;
        least 100,000/mm3* *unless there is bone marrow involvement with lymphoma Hepatic:&#xD;
        Bilirubin less than 3 mg/dL AST/ALT less than 2 times normal Renal: Creatinine less than&#xD;
        2.1 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: LVEF greater than&#xD;
        45% by MUGA or echocardiogram Other: No prior malignancy within the past 10 years except&#xD;
        squamous cell carcinoma or basal cell carcinoma of the skin or cervical cancer No evidence&#xD;
        of infection HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients&#xD;
        must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior rituximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sein Aung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harry &amp; Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Square Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2001</verification_date>
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>May 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2004</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

